Today, more in our series on Afrezza in the Real World…Some analysts are giving not-so-positive outlooks on Afrezza based on early financial reports that the new inhaled insulin raised just a measly $1.1 million in its first weeks on the mark…
SOURCE: Healthline RSS Feed – Read entire story here.